| Gene name: | HSPA5 |
| Aging type: | Prevent |
| Aging characteristic: | Others |
| Tissue type: | Bone |
| Cell name: | A2780 |
| Gene ID: | 3309 |
| Category: | protein coding |
| Phenotype: | Ovarian cancer |
| Experimental category: | L |
| PMID: | 24756776 |
| Experiment: | Knockdown//SA-β-gal activity assay |
| Description: | Seven days after 3 μg/ml cisplatin treatment, <20% of the A23187-treated A2780 cells showed positive SA-β-gal staining, whereas cells treated with cisplatin only were almost all positively stained. To confirm the specific anti-senescence effect of GRP78, GRP78-siRNA was transfected into the A23187-treated A2780 cells. After 3 days, the treated cells were exposed to 3 μg/ml cisplatin and incubated with complete medium. After 6 days,the cells exhibited 90% positive SA-β-gal staining. |
| Target gene: | P53//CDC2 |
| Official symbol(s): | P53//CDK1 |
| R-AG-Target gene: | --//-- |
| Subcategory: | Unclear |
| Target gene experiment: | Knockdown//Western blot |
| Target gene description: | The results showed that GRP78 protein levels were significantly decreased after GRP78-siRNA transfection in the A2780 cells. Accompanied by knockdown of GRP78, P53 levels were significantly increased and CDC2 levels were significantly decreased. There were no changes in the protein levels of P21 and p-CDC2. This suggests that P53 and CDC2 are involved in cisplatin-induced senescence of A2780 cells. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...